相关临床试验
4
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
1
25.0%
招募中
2
50.0%
撤回
1
25.0%
暂无批准数据
- CellProthera plans to initiate a Phase III trial in Q1 2027 for ProtheraCytes stem cell therapy targeting heart failure patients post-myocardial infarction. - The study will enroll 300-400 patients across 50 sites in the US and Europe, with potential expansion to Asia. - The therapy aims to repair damaged cardiac tissue and reduce scar formation without immunosuppressants, particularly benefiting 5-10% of patients with extensive cardiac damage. - CellProthera acquired transendocardial catheter rights from Celyad Oncology to enable precise CD34+ stem cell delivery to damaged heart tissue.
- DelveInsight's 2025 pipeline report reveals over 30 companies are actively developing more than 40 therapies for myocardial infarction treatment across various clinical stages. - Key late-stage developments include Faraday Pharmaceuticals' FDY-5301 in Phase III trials and Acticor Biotech's Glenzocimab in Phase II, targeting different mechanisms of cardiac injury prevention. - Recent clinical milestones include Faraday's completion of patient enrollment in its pivotal Phase III trial and mixed results from other advanced programs like CSL112's failed Phase III endpoint. - The pipeline encompasses diverse therapeutic approaches including anti-ischemic agents, platelet inhibitors, and SGLT2 inhibitors, addressing various aspects of myocardial infarction pathophysiology.
- CellProthera has selected CELLforCURE by SEQENS as its CDMO partner for Phase 3 manufacturing of ProtheraCytes, an autologous expanded CD34+ stem cell therapy for severe heart attack patients. - The partnership will begin with technology transfer in 2025, with clinical batch production expected to start in 2026 following favorable FDA feedback on the Phase 3 trial design. - ProtheraCytes aims to improve heart failure event-free survival following severe heart attacks and has shown promising results in Phase 1/2b studies as it advances toward market authorization.
- CellProthera has begun the PERFECT study, a 10-year observational follow-up to assess ProtheraCytes' long-term safety and efficacy after acute myocardial infarction. - The study will monitor biological markers like NT-proBNP and evaluate patients' clinical status, comparing them to those receiving standard care. - Initial EXCELLENT trial results showed ProtheraCytes improved prognostic markers, suggesting an anti-remodeling effect on cardiac tissue. - This research aims to confirm ProtheraCytes' ability to regenerate and repair heart tissue, potentially reducing the high mortality rate associated with post-AMI complications.
- CellProthera has secured FDA alignment on the design for a pivotal Phase III trial of ProtheraCytes, a cell therapy for acute myocardial infarction (AMI). - The Phase III trial will be conducted in the US and Europe, involving a larger patient cohort with a two-year follow-up to assess long-term efficacy. - ProtheraCytes showed improved left ventricular volumes and myocardial segment viability in the Phase II EXCELLENT study, indicating promising efficacy signals. - The planned Phase III trial will be a randomized, open-label study with standard-of-care post-AMI treatment as the control, focusing on a composite endpoint.
